CalciMedica (CALC) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CalciMedica, Inc. has announced that the FDA cleared their Investigational New Drug application for a Phase 2 trial of their lead product candidate, Auxora, for severe acute kidney injury associated with respiratory failure. The trial, named KOURAGE, is set to begin in the first half of 2024, with results expected in 2025. This groundbreaking study will assess the effectiveness of Auxora in reducing kidney injury and improving survival rates, filling a significant gap as there are currently no approved therapies for acute kidney injury. The company also shared pipeline updates, including anticipated data releases for other trials and future IND submissions, while projecting a cash runway into the latter half of 2025.
For further insights into CALC stock, check out TipRanks’ Stock Analysis page.